HeartBeam Announces Proposed Public Offering: Key Details for Investors
HeartBeam Announces Proposed Public Offering of Common Stock: Key Details for Investors
Date: April 14, 2026
Company: HeartBeam, Inc. (NASDAQ: BEAT)
Location: Santa Clara, CA
Key Highlights of the Announcement
-
Proposed Public Offering: HeartBeam, Inc. has announced the commencement of an underwritten public offering of shares of its common stock (or equivalents). All securities in this offering will be issued by HeartBeam itself.
-
Use of Proceeds: The net proceeds from this offering are intended for several strategic initiatives:
- Commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system
- Further development of its extended-wear ECG patch and heart attack detection initiatives
- Enhancement of artificial intelligence (AI) capabilities
- General working capital and other corporate purposes
-
Bookrunner: Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the proposed offering.
-
Registration Statement: The offering will be made pursuant to a shelf registration statement on Form S-3/A (File No. 333-293307), filed with and declared effective by the U.S. SEC in March 2026.
Implications for Shareholders and Potential Share Price Impact
-
Potential Dilution: As with any public offering of common stock, existing shareholders may face dilution of their holdings depending on the size and pricing of the offering. The exact terms, including number of shares and pricing, have not yet been determined and are subject to market conditions.
-
Strategic Investments: Proceeds will be channeled into the company’s core growth areas, including the commercialization of its recently FDA-cleared technologies and further innovation in AI-driven cardiac diagnostics. Success in these initiatives could drive future revenue growth and positively impact share value.
-
Regulatory Status: HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2024 and December 2025, respectively. This regulatory progress significantly enhances the company’s commercial prospects and could be price-sensitive information for investors.
-
Intellectual Property Position: The company holds over 20 issued patents, strengthening its competitive moat in cardiac technology.
-
Forward-Looking Statements: Investors should note the inherent risks and uncertainties associated with the business, including those detailed in HeartBeam’s filings with the SEC. Future results may differ materially from forward-looking statements.
How to Access the Offering Documents
Investors can review the preliminary prospectus supplement and accompanying prospectus once filed with the SEC, available at www.sec.gov. Additional copies may be obtained by contacting Titan Partners Group LLC at 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246, or by email at [email protected].
About HeartBeam, Inc.
HeartBeam is a medical technology innovator focused on transforming cardiac care through portable, cable-free devices capable of collecting ECG signals in 3D and synthesizing them into a 12-lead ECG. Its technology is designed to provide actionable cardiac insights remotely, enabling physicians to monitor patients and detect acute cardiac conditions outside medical facilities.
For more information, visit HeartBeam.com.
Contact Information
Disclaimer
This article contains forward-looking statements subject to risks and uncertainties, including those described in HeartBeam’s SEC filings. Investors are urged to review all relevant documents and consider these risks before making investment decisions. This is not an offer to sell, nor a solicitation of an offer to buy, any securities. The offering is subject to market conditions and may not be completed as described. Past regulatory approvals do not guarantee future results.
View HeartBeam, Inc. Historical chart here
